213 related articles for article (PubMed ID: 32740556)
1. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
Wang JCC; Swainson J
J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
[No Abstract] [Full Text] [Related]
2. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
3. Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor.
Katz RB; Toprak M; Wilkinson ST; Sanacora G; Ostroff R
Gen Hosp Psychiatry; 2018; 54():62-64. PubMed ID: 30100209
[No Abstract] [Full Text] [Related]
4. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Ludwig VM; Sauer C; Young AH; Rucker J; Bauer M; Findeis H; Ritter P
CNS Drugs; 2021 Aug; 35(8):881-892. PubMed ID: 34283390
[TBL] [Abstract][Full Text] [Related]
5. The TNF-alpha inhibitor etanercept as monotherapy in treatment-resistant depression - report of two cases.
Schmidt FM; Kirkby KC; Himmerich H
Psychiatr Danub; 2014 Sep; 26(3):288-90. PubMed ID: 25191779
[No Abstract] [Full Text] [Related]
6. Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases.
Bartova L; Vogl SE; Stamenkovic M; Praschak-Rieder N; Naderi-Heiden A; Kasper S; Willeit M
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2183-4. PubMed ID: 26302763
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
Singh B; Bobo WV; Rasmussen KG; Stoppel CJ; Rico JA; Schak KM; Biernacka JM; Frye MA; Vande Voort JL
J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31721482
[No Abstract] [Full Text] [Related]
8. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
9. The use of monoamine oxidase inhibitors in primary care.
Culpepper L
J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
[TBL] [Abstract][Full Text] [Related]
10. Ketamine for the treatment of depression.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
[TBL] [Abstract][Full Text] [Related]
11. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
12. Antidepressant response and subthreshold bipolarity in "unipolar" major depressive disorder: implications for practice and drug research.
Rihmer Z; Dome P; Gonda X
J Clin Psychopharmacol; 2013 Aug; 33(4):449-52. PubMed ID: 23775059
[No Abstract] [Full Text] [Related]
13. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
15. Drugs for depression.
Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
[No Abstract] [Full Text] [Related]
16. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
[No Abstract] [Full Text] [Related]
17. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
[TBL] [Abstract][Full Text] [Related]
18. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
Włodarczyk A; Cubała WJ
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
[TBL] [Abstract][Full Text] [Related]
19. [MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].
Köhler S; Stöver LA; Bschor T
Fortschr Neurol Psychiatr; 2014 Apr; 82(4):228-36; quiz 237-8. PubMed ID: 24710679
[No Abstract] [Full Text] [Related]
20. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
Flockhart DA
J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
